Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 3/20 | 0.33 |
| ▸ | TREH | O43280 | 1/20 | 0.33 |
| ▸ | CDA | P32320 | 5/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | PYGM | P11217 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509721 | 1.00 | LMNA (0.44) | LMNAGBA1NLRP3PYGBTREH | |
| SCHEMBL246685 | 1.00 | LMNA (0.44) | LMNAGBA1NLRP3PYGBTREH | |
| SCHEMBL346819 | 1.00 | LMNA (0.44) | LMNAGBA1NLRP3PYGBTREH | |
| SCHEMBL14124884 | 1.00 | LMNA (0.44) | LMNAGBA1NLRP3PYGBTREH | |
| Water SCHEMBL6533488 | 0.98 | LMNA (0.42) | LMNAGBA1NLRP3PYGBTREH | |
| Water SCHEMBL27487332 | 0.98 | LMNA (0.42) | LMNAGBA1NLRP3PYGBTREH | |
| Phosphoric Acid SCHEMBL21495145 | 0.93 | LMNA (0.39) | LMNAGBA1NLRP3TREH | |
| SCHEMBL16684264 | 0.87 | — | — | |
| SCHEMBL6531031 | 0.84 | LMNA (0.35) | LMNAGBA1 | |
| SCHEMBL14817456 | 0.80 | LMNA (0.37) | LMNAGBA1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2025054293-A1 | BIOMARKER FOR PROSTATE CANCER | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-03-13 | — | — | WO | claimed |
| US-20250076301-A1 | BIOMARKER FOR PROSTATE CANCER | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-03-06 | — | — | US | claimed |
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| CN-114026427-B | Marker for diagnosing kidney disease and diagnostic method | 深圳市中医院 | 2023-11-17 | — | — | CN | claimed |
| CN-115786450-B | 1, 5-dehydration-D-sorbitol determination kit and preparation method thereof | 广东优尼德生物科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116670273-A | Method for measuring in a biosensor | 北卡罗来纳大学教堂山分校 | 2023-08-29 | — | — | CN | claimed |
| US-20230221332-A1 | EYE DISEASE EVALUATION METHOD | SHIMADZU CORPORATION (JP) | 2023-07-13 | — | — | US | claimed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| EP-2606040-B1 | AGROCHEMICAL ADJUVANTS AND FORMULATIONS | CRODA INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-9089132-B2 | Agrochemical adjuvants and formulations | CRODA, INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-8608922-B2 | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2013-12-17 | — | — | US | claimed |
| CN-103403548-A | Means and method for predicting diabetes | METANOMICS HEALTH GMBH | 2013-11-20 | — | — | CN | claimed |
| US-20130295692-A1 | MEANS AND METHODS FOR PREDICTING DIABETES | METANOMICS HEALTH GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| US-20130244877-A1 | Agrochemical Adjuvants and Formulations | CRODA, INC. (US) | 2013-09-19 | — | — | US | claimed |
| CN-102483416-A | Means And Methods For Diagnosing Prostate Carcinomas | METANOMICS HEALTH GMBH DE | 2012-05-30 | — | — | CN | claimed |
| EP-2005189-B1 | MEANS AND METHOD FOR DIAGNOSING DIABETES type II | METANOMICS GMBH (DE) | 2010-12-29 | — | — | EP | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| CN-101443663-A | Means and methods for diagnosing diabetes | METANOMICS GMBH (DE) | 2009-05-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | LMNA 3336/4885GBA1 120/4885NLRP3 4382/4885 |
| US-20130244877-A1 | Agrochemical Adjuvants and Formulations | MGLL, ELOVL3, ELOVL6 | LMNA 2392/4885GBA1 269/4885NLRP3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.